C43 - Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice
- Resource Type
- Article
- Source
- In
Annals of Oncology October 2017 28 Supplement 6:vi37-vi37 - Subject
- Language
- ISSN
- 0923-7534